A Commotion in the Skin: Developing Melanoma Immunotherapies
- 23 March 2022
- journal article
- review article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (8) , 2055-2060
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Krebshilfe
- Wilhelm Sander-Stiftung
- Deutsche Forschungsgemeinschaft (390900677, FOR2314, RO 764/15-2)
This publication has 51 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- T-helper-1-cell cytokines drive cancer into senescenceNature, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasionBlood, 2009
- Heterogeneity of T-Cell Clones Infiltrating Primary Malignant MelanomasJournal of Investigative Dermatology, 2006
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991
- Cultured Epidermal Langerhans Cells Activate Effector T Cells for Contact SensitivityJournal of Investigative Dermatology, 1990
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985